Medical Futures Signs North American Licensing Rights to New Biologic Agent for Ulcerative Colitis
Posted on: Monday, 7 April 2008, 12:00 CDT
TORONTO, April 7 /PRNewswire/ -- Medical Futures Inc. has licensed MUTAFLOR(R) for the North American market. MUTAFLOR(R) is a drug used in remission maintenance of Ulcerative Colitis. Since its discovery in 1917, MUTAFLOR(R) has been available in the German marketplace through a subsidiary of Pharma-Zentrale GmbH, Ardeypharm GmbH. MUTAFLOR(R) has shown clinical efficacy in phase III clinical trials and has shown a perfect safety record since 1917. Ulcerative colitis is an Inflammatory Bowel Disease that affects 500,000 Americans and 60,000 Canadians.
"Medical Futures Inc. is excited about partnering with Pharma-Zentrale GmbH for MUTAFLOR(R)," says Dr. Par Nijhawan, Chief Medical Officer of Medical Futures Inc., who believes that MUTAFLOR(R) will help improve the options available for Ulcerative Colitis patients.
"Medical Futures has created a therapeutic focus and a strong product offering for the gastroenterology market in North America," says Hans Proppert, President and Chief Executive Officer of Pharma Zentrale GmbH. "With MUTAFLOR(R) in their capable hands, we are confident of its success in an important market for us."
About MUTAFLOR(R)
MUTAFLOR(R) has data proving equal efficacy when compared to 5-ASA products in remission maintenance of Ulcerative Colitis. It is taken as an oral capsule format that saves patients from intravenous infusions or self administration of subcutaneous needles. This, together with the clinical evidence, is one advantage of MUTAFLOR(R) over all other biologics available on the market.
About Medical Futures Inc.
Medical Futures Inc. is a niche pharmaceutical company that has a focus on gastrointestinal therapy. Medical Futures is dedicated to improving quality of life and provides safe, effective and affordable medicines. These medicines include:
Florastor(TM): The world's number one probiotic that has proven efficacy in treating and preventing diarrhea from various causes including Pediatric Diarrhea, Antibiotic Associated, Clostridium Difficile and Travellers' Diarrhea.
Iberogast(R): The only treatment available for Non-ulcer Dyspepsia and Irritable Bowel Syndrome.
Zingo(TM) is a needle-free, easy-to-administer, single-use system that delivers sterile lidocaine powder into the epidermis of the skin that provides topical, local analgesia in one minute.
SANVAR(R) is the only somatostatin analogue to have demonstrated statistically significant benefits in the treatment of esophageal variceal bleeding in association with endoscopic therapy in a placebo-controlled clinical study (NEJM, 2001).
Medical Futures Inc.
CONTACT: Ky To, VP Marketing & Sales, Tel.: (905) 731-0294, Fax: (905)731-2873, ky@medfutures.com
Source: PRNewswire
Related Articles
- Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
- New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients With Recent Disease Onset or Long-Standing Disease
- Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
- Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
- Analysis: Colitis Market to Hit $1.1B
- Salix Seeks Marketing Extension for Ulcerative Colitis Drug
- University of Pittsburgh Clinical Study to Test Antibody Therapy for Patients With Severe Ulcerative Colitis
- Good bacteria useful for ulcerative colitis
- REMICADE Granted Priority Review By U.S. Food and Drug Administration for Treatment of Ulcerative Colitis; First Biologic to Show Efficacy in Phase III Trials for Ulcerative Colitis
 |
 |
User Comments (0)
RSS Feeds